Phreesia Inc logo

Phreesia Inc(PHR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 19 days
PROFIT SINCE LAST BUY
+5.31% ▲
LAST CLOSE
$12.69
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PHR

11/13/2026: PHR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Phreesia Inc is a healthcare technology company providing a software platform that automates administrative tasks like patient registration and payments. The company is known for its strong position in the digital front door space and its ability to integrate with major electronic health record systems. Its primary growth opportunity lies in expanding its platform across more medical specialties and scaling its high-margin Life Sciences advertising network. Key risks include intense competition from integrated EHR vendors, potential macroeconomic pressures on physician budgets, and the need to achieve sustainable profitability. The stock is best suited for growth-oriented investors who can tolerate volatility while monitoring progress toward financial targets.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitPhreesia offers high revenue growth potential by digitizing the fragmented ambulatory healthcare market.
Momentum investorMixed fitThe stock often reacts significantly to revenue growth beats or misses, requiring a positive momentum signal to justify entry.
Value investorWeak fitThe company is not yet consistently profitable, making traditional value metrics like P/E ratios inapplicable.
Dividend investorWeak fitPhreesia does not pay dividends and prioritizes capital reinvestment.
Low-risk investorWeak fitHigh growth, non-profitable SaaS companies typically experience higher volatility than established, cash-flow-positive firms.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighAs a growth stock, Phreesia's price can fluctuate significantly based on interest rates and quarterly performance.
Valuation riskMedium / highHigh price-to-sales ratios create sensitivity to any slowdown in growth expectations.
Competition risk (EHR integration)Medium / highLarge EHR vendors like Oracle may continue to bundle competing features into their existing platforms.
Business qualityMediumWhile the platform has sticky attributes, the company must prove long-term sustainable profitability.
Dividend incomeLow / noneIncome-focused investors will not find suitability here as no payouts are offered.
Execution riskMediumScaling sales and onboarding in a fragmented healthcare market requires consistent, effective execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 787.68M USD
Price to earnings Ratio 74.65
1Y Target Price 13.87
Price to earnings Ratio 74.65
1Y Target Price 13.87
Volume (30-day avg) 645.7K shares
Beta 0.72
52 Weeks Range 7.77 - 21.77
Updated Date 11/14/2026
52 Weeks Range 7.77 - 21.77
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.17

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
4 / 4
30-Day BUY Count Change
+2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 10.92%
Avg. Invested days 36
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PHR receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
PHR has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2026 versus FY2025, strong earnings growth (+103.9%) and solid cash generation (FCF margin 14.1%) are partially offset by soft profitability (net margin 0.5%).

Financial Health Rating

★★★★★
PHR's financial health is supported by solid cash strength, including free-cash-flow generation (14.1% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is PHR's strongest growth driver at +716.6% FY2026 versus FY2025 (strong, 5 stars). Revenue growth (+14.5%, solid) and earnings growth (+103.9%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 95.7% and approximately 79.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.35% supports management-shareholder alignment.

Top 5 Institutional Investors

Pale Fire Capital SE 14.38%
BlackRock Inc 11.31%
AQR Capital Management LLC 5.08%
Vanguard Portfolio Management, LLC 4.81%
Vanguard Capital Management, LLC 4.11%

Unit Economics (Per $1K Revenue)

★★★★★
PHR generates approximately $679 of gross profit, $-14 of operating income, and $141 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins and solid cash conversion support a 3-star rating, while capital efficiency is weak.

Economic Dimensions

★★★★★
Effective Tax Rate: 125.79%

Quantitative Style Profile

★★★★★
PHR has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Phreesia PlatformSubscription and transaction-based fees from healthcare providers for patient intake software.This is the core SaaS engine of the company, providing recurring, predictable revenue.
Life SciencesRevenue from pharmaceutical companies for targeted patient education and advertising.This is a high-margin, network-based segment that leverages patient data to drive growth.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE 74.65
Forward PE 14.18
Enterprise Value 778.34M
Price to Sales(TTM) 1.55
Enterprise Value 778.34M
Price to Sales(TTM) 1.55
Enterprise Value to Revenue 1.53
Enterprise Value to EBITDA 15.56
Shares Outstanding 62.07M
Shares Floating 49.23M
Shares Outstanding 62.07M
Shares Floating 49.23M
Percent Insiders 6.35
Percent Institutions 95.72

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.